Cell Type Specific Expression of Steroid 5α-Reductase 2

Silver, Richard I.; Wiley, Elizabeth L.; Thigpen, Anice E.; Guileyardo, Joseph M.; McConnell, John D.; Russell, David W.

doi:10.1016/s0022-5347(17)32758-1

Cited by 89 publications

(49 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Silver et al (1994) have reported that human 5 R-II in some BPH specimens is predominantly in the basal epithelial cells whereas in other specimens it is in both stroma and basal epithelial cells. They were, however, unable to detect 5 R-I in prostate by employing specific antibodies.…”

Section: Discussionmentioning

confidence: 99%

“…There is general consensus that 5 R-II is expressed in both the normal prostate and in BPH (Silver et al 1994, Levine et al 1996; however the presence of the 5 R-I enzyme and its encoding mRNA have been controversial. Bonnet et al (1993) demonstrated, using Northern analysis, that 5 R-I and -II were expressed in human prostate and suggested that both enzymes were located predominantly in epithelial cells.…”

Section: Discussionmentioning

confidence: 99%

“…However the possible presence of 5 R-I in human prostate remains controversial. Whilst some studies reported the absence of 5 R-I mRNA and protein in human prostate (Thigpen et al 1993, Silver et al 1994, other investigations demonstrated 5 R-I expressed in primary prostate tissue by Northern analysis (Bonnet et al 1993) and in cultures of epithelial cells (Hirsch et al 1993). However neither study addressed the important issue of whether the two isoenzymes were expressed in intact BPH tissue or established their cellular distribution within the gland.…”

Section: Introductionmentioning

confidence: 96%

See 2 more Smart Citations

The localisation and expression of 5 alpha-reductase types I and II mRNAs in human hyperplastic prostate and in prostate primary cultures

Habib

Ross²,

Bayne³

et al. 1998

Journal of Endocrinology

View full text Add to dashboard Cite

The expression and localisation of mRNAs for 5 reductase Type I (5 R-I) and Type II (5 R-II) isoenzymes in human benign prostatic hyperplasia (BPH) were investigated by RT-PCR and by in situ hybridisation (ISH) using digoxigenin labelled riboprobes. In addition, we also examined the isoenzymes mRNA expression in primary BPH cultures of separated stroma/fibroblast and epithelial cells to determine whether primary cultures are appropriate models in which to investigate 5 R activity and regulation. The results demonstrated conclusively the presence of mRNA encoding both isoenzymes in all specimens so far examined. Additionally, the presence of a functional 5 R-I and -II activity in BPH was confirmed by enzyme assays. ISH studies localised the mRNA expression to both the fibroblast/stromal component as well as the epithelial cells of the hyperplastic tissue. In the glandular regions the expression for both isoenzymes was particularly strong in the basal layers of the epithelium whereas mRNA expression in the secretory cells was less pronounced. Expression of 5 R-I and -II mRNAs in fibroblast was on the other hand variable with high expression in some areas and little in others. These findings were supported by our primary culture experiments which demonstrated that both the fibroblast and epithelial cells maintain a capacity to express both isoenzymes in vitro. In the case of the fibroblast, the capacity to express the isoenzymes was maintained following the sequential passaging of the cells up to passage 6, after which the cells no longer expressed either isoenzyme.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 96%

See 1 more Smart Citation

The localisation and expression of 5 alpha-reductase types I and II mRNAs in human hyperplastic prostate and in prostate primary cultures

Habib

Ross²,

Bayne³

et al. 1998

Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…The polyclonal antibody for 17b-hydroxysteroid dehydrogenase type 5 (17b-HSD5) was raised in a rabbit against a synthetic peptide corresponding to amino acids 297-320 for 17b-HSD5 and was kindly provided by Dr V Luu (Laval University Hospital Center, Que´bec, Canada) (Pelletier et al 1999). Characterization of these three antibodies was confirmed by immunoblotting, and the use of antibodies for 5a-reductase type 2 and 17b-HSD5 on immunohistochemistry has been previously reported (Thigpen et al 1993, Silver et al 1994, Pelletier et al 1999. mAb against AR was purchased from DAKO Corporation (Carpinteria, CA).…”

Section: Patients and Tissuesmentioning

confidence: 99%

In situ androgen producing enzymes in human prostate cancer

Nakamura

Suzuki

Nakabayashi

et al. 2005

Endocr Relat Cancer

View full text Add to dashboard Cite

Androgens have been proposed to be actively produced in situ in human prostate cancer. These locally produced androgens have also been considered to play important roles in the pathogenesis and development of prostate cancer. Therefore, it is important to examine the status of this in situ androgen metabolism and/or synthesis in detail in order to improve the clinical response to hormonal therapy in patients diagnosed with prostate cancer. Several studies have previously demonstrated the expression of androgen-producing enzymes such as 5a-reductase types 1 and 2, and 17b-hydroxysteroid dehydrogenase type 5 (17b-HSD5), in human prostate carcinoma cells. However, their biological significance has remained largely unknown. In this study, we evaluated the immunoreactivities of these steroidogenic enzymes in human prostate cancer obtained from surgery (n=70), and correlated the findings with clinicopathological features of the patients. 17b-HSD5 immunoreactivity was detected in 54 cases (77%), 5a-reductase type 1 in 51 cases (73%) and 5a-reductase type 2 in 39 cases (56%). 5a-reductase type 2 immunoreactivity was significantly correlated with that of androgen receptor (AR), and 17b-HSD5 positive cases were significantly associated with clinical stage (TNM stage pT3 vs pT2). These data all suggest that androgenproducing enzymes, such as 5a-reductase type 1 and type 2, and 17b-HSD5 are expressed in a majority of prostate cancers, and are involved in the local production and actions of androgens in prostate cancers.

show abstract

“…[35,36] Immunohistochemical studies using 5α-reductase type 2-specific antibodies have demonstrated that this enzyme is primarily localized in the stroma of the gland. [37] The stromal cells have been considered to play a primary role in androgen-dependent prostatic growth. [38,39] …”

Section: α-Reductase Types and Their Distributionmentioning

confidence: 99%

Current status of 5α-reductase inhibitors in the treatment of benign hyperplasia of prostate

Kumar¹,

Wahane²

2008

Indian J Med Sci

View full text Add to dashboard Cite

Benign prostatic hyperplasia (BPH) is a common problem in aging menof BPH include increased urinary frequency, urgency, intermittency; nocturia; decreased force of stream; hesitancy and straining that are usually associated with complications such as acute urinary retention, urinary incontinence, recurrent urinary tract infection, hematuria, renal failure, and bladder stone. [4][5][6][7][8][9] The primary goal for treating symptomatic BPH is to improve urine ß ow, for which both surgical and nonsurgical approaches are available. Surgical treatment for BPH is usually indicated in recurrent cases of urinary retention, urinary tract infections, hematuria, and in azotemia.

show abstract

Cell Type Specific Expression of Steroid 5α-Reductase 2

Cited by 89 publications

References 11 publications

The localisation and expression of 5 alpha-reductase types I and II mRNAs in human hyperplastic prostate and in prostate primary cultures

The localisation and expression of 5 alpha-reductase types I and II mRNAs in human hyperplastic prostate and in prostate primary cultures

In situ androgen producing enzymes in human prostate cancer

Current status of 5α-reductase inhibitors in the treatment of benign hyperplasia of prostate

Contact Info

Product

Resources

About